Alvarez-Larrán Alberto, Bellosillo Beatriz, Martínez-Avilés Luz, Saumell Silvia, Salar Antonio, Abella Eugenia, Gimeno Eva, Serrano Sergi, Florensa Lourdes, Sánchez Blanca, Pedro Carmen, Besses Carles
Haematology Department, Hospital del Mar, IMIM, Barcelona, Spain.
Br J Haematol. 2009 Sep;146(5):504-9. doi: 10.1111/j.1365-2141.2009.07804.x. Epub 2009 Jul 8.
Postpolycythaemic myelofibrosis (PPMF) is a known complication of polycythaemia vera (PV) but information regarding its incidence and predisposing factors is not well defined. In 116 subjects consecutively diagnosed with PV in a single institution (median age 62 years, range: 20-88), the probability of PPMF was analysed by the Kaplan-Meier method, followed by the log-rank test. With a mean follow-up of 8 years (95% confidence interval: 6.6-9), 17 patients had evolved into PPMF (15%). The probability of evolution to PPMF was 16% at 10 years and 34% at 15 years. Age, gender, spleen size, leucocytosis, thrombocytosis or cytoreductive treatment were not associated with an increased risk of PPMF. The actuarial probability of PPMF at 15 years was higher in those patients presenting at diagnosis with endogenous megakaryocytic colony formation (59% when present versus 10% when absent, P = 0.03), an elevated serum lactate dehydrogenase (LDH) level (69% vs. 23% in patients with normal LDH, P = 0.04), and in those who were heterozygous for the JAK2 V617F mutation (55% vs. 17% in heterozygotes, P = 0.04). In conclusion, PPMF is a frequent complication in PV patients at 15 years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden.
真性红细胞增多症后骨髓纤维化(PPMF)是真性红细胞增多症(PV)的一种已知并发症,但关于其发病率和诱发因素的信息尚不明确。在一家机构连续诊断出的116例PV患者(中位年龄62岁,范围:20 - 88岁)中,采用Kaplan-Meier方法分析PPMF的发生概率,随后进行对数秩检验。平均随访8年(95%置信区间:6.6 - 9),17例患者发展为PPMF(15%)。10年时发展为PPMF的概率为16%,15年时为34%。年龄、性别、脾脏大小、白细胞增多、血小板增多或细胞减灭治疗与PPMF风险增加无关。诊断时出现内源性巨核细胞集落形成的患者15年时PPMF的精算概率更高(存在时为59%,不存在时为10%,P = 0.03),血清乳酸脱氢酶(LDH)水平升高的患者(LDH正常的患者为69%对23%,P = 0.04),以及JAK2 V617F突变杂合子患者(杂合子中为55%对17%,P = 0.04)。总之,PPMF是PV患者15年时常见的并发症,LDH升高、内源性巨核细胞集落形成或JAK2 V617F等位基因负荷高的患者风险更高。